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Experts’ experience 
Loeb et al. [1] published the results of a study on 5880 men diagnosed with prostate cancer from 
2005 to 2007, including 4325 who had radical prostatectomy (RP) and 1555 treated with radiation 
therapy. They adopted the recently proposed five-tiered Gleason grade groups (GGGs; i.e., Prognostic 
grade groups [PGGs]), in which Gleason 6 is GGG 1, Gleason 3 + 4 is GGG 2, Gleason 4 + 3 is GGG 3, 
Gleason 8 is GGG 4 and Gleason 9–10 is GGG 5. The authors found that the newly proposed GGGs offer 
a simplified, user-friendly nomenclature to aid in patient counseling, with similar predictive accuracy in a 
population-based setting to previous classifications. 
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The study published by Loeb et al. [1] has suggested to our transnational group of pathologists, to 
investigate the prognosis in a series of RP with acinar adenocarcinoma diagnosed in Ancona from 2005 to 
2007 with Gleason score 3 + 3 = 6 (i.e., GGG 1) based on the 2005 International Society of Urological 
Pathology (IUSP) Modified Gleason System [2]. In a group of 395 cases, 151 patients with Gleason score 
3 + 3 = 6 (GGG 1) acinar adenocarcinoma were identified. 147 (97%) out of 151 patients are alive 
without tumor relapse and biochemical recurrence after a period of follow-up ranged from 8 to 10 years. 
Four (3%) out of 151 patients had relapse at the pelvic lymph nodes and then distant metastases, 
three of them were still alive at a mean follow-up of 82 months and one dead after 108 months. The 
histological slides of these four patients were reviewed, applying the Gleason grading based on the 2014 
ISUP Modified Gleason System [3]. One of the three patients, still alive, had a Gleason score 6 (GGG 1) 
and nonfocal intraprostatic positive margins. The other two patients, still alive, showed a cribriform 
component composed of small cribriform glands with smooth contours and the dead patient had glands 
with glomeruloid features. The cribriform glands and glomeruloid pattern represented approximately 5% 
of the acinar adenocarcinoma in each case. 
Experts’ comments 
Our observations in terms of morphology and prognosis are not different from those made by 
Ross et al. [4], who reviewed the slides of 19 cases of radical prostatectomy with adenocarcinoma 
Gleason score <6 that showed pelvic lymph node metastases. All cases submitted to histopathologic 
review showed higher grade than originally reported by the pathologists. In particular, two cases were 
upgraded to 4 + 3 = 7 with both poorly formed and cribriform glands; eleven cases with glomeruloid 
structures and small to large cribriform glands were upgraded to 3 + 4 = 7. 
The cribriform component observed in our two cases was composed of small cribriform glands 
with smooth contours, considered as Gleason pattern 3 on the base of 2005 ISUP Modified Gleason 
System [5]. 
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In 2008, Latour et al. [6] presented a set of images representing examples of cribriform pattern 3 
to experts in uropathology. The majority of the participants to this study have considered the cribriform 
patterns as pattern 4; furthermore, the most of the cribriform lesions (i.e., 73%) were associated with a 
pattern 4 in other parts of the biopsy. The conclusion of this study was that the vast majority of small 
cribriform glands should be considered as Gleason pattern 4. 
In the 2005 conference organized by the ISUP [5], the few cases of adenocarcinoma with 
glomeruloid features were considered as Gleason score 3 + 3 = 6, only some participants supported the 
idea that all small glomeruloid structures had to be reported as a pattern 4. In a subsequent study, prostate 
biopsies with adenocarcinoma with glomeruloid features were assessed to see whether glomerulations and 
concurrent high-grade adenocarcinoma were associated in the same core. Glomerulations were associated 
with high-grade adenocarcinoma, predominantly of pattern 4 in 80% of the cases in the same biopsy, and 
often with a transition to larger cribriform glands. Only in 16% of the cases the glomeruloid structures 
were associated with pattern 3 adenocarcinoma [7]. On the base of such an observation, it was suggested 
that glomeruloid structures represent an early stage in the formation of cribriform pattern 4 and should be 
all reported as pattern 4 [8]. 
In the 2014 ISUP Modified Gleason System [3], the cribriform glands, regardless of their border, 
and the glands with glomeruloid features have to be considered as a Gleason pattern 4. This means that 
three of our patients belong to the GGG 2 when the 2014 ISUP Modified Gleason System is applied. 
In our three cases (GGG 1) that showed metastasis, the percentage of Gleason pattern 4 
represented approximately 5% of the tumor. Originally, McNeal et al. [9] had proposed to report the 
percentage of Gleason grade 4/5, afterward the same group showed that this feature was an independent 
predictor of recurrence after RP [10]. In 2007, in a paper entitled ‘Should the Gleason score be replaced 
with the amount of high-grade prostate cancer?’, Vis et al. demonstrated that the amount of high-grade 
cancer is more important than the Gleason system in predicting prognosis, both in biopsy and in RP 
specimens [11]. In particular, the authors have suggested that in addition to the Gleason score, the amount 
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of Gleason patterns 4/5 should also be mentioned in the pathology report [11]. In the 2014 ISUP 
conference, emerging issues related to grading of adenocarcinoma were also discussed; in addition to the 
prognostic grade groups, the percentage Gleason pattern 4 present in biopsy cores should be present in the 
pathological report. As quoted in a recent editorial by Egevad et al., “The reporting of percentage Gleason 
4 tumor tissue has the advantage that this highlights if a cancer is at the lower or higher end of a grade” 
[12]. As shown by Sauter et al. in a very recent publication, “there is a biological continuum within 
Gleason score 3 + 4 = 7 and 4 + 3 = 7 tumors that is reflected in clinical outcome” [13]. 
We have also revised the slides of the other 147 patients alive without biochemical recurrence 
and no tumor relapse. A Gleason score 3 + 3 = 6, that is, GGG 1, was confirmed in all cases. Our results 
are in agreement with the study by Kweldam et al. [14]. Their investigation was based on 1101 
consecutive RP patients operated between March 1985 and July 2013. They demonstrated that “disease-
specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy” 
[14], that is, none of their 449 patients with Gleason score ≤6 showed disease-specific death and 
metastasis. 
Our findings on GGG1 cases are in agreement with the observation made by Epstein et al. [15] in 
a recently published study on contemporary prostate cancer grading issue, in which they showed that the 
GGG system is a validated alternative to the Gleason score. In agreement with these authors, the new 
prostate cancer grading system reflects prognosis more accurately, being at the same time simpler to 
define. 
Our findings are supported by a recent observation made in a study, in which Rubin and his 
coworkers [16] have investigated the genomic background for PGGs using whole-exome and whole-
genome sequencing data from 426 localized prostatic adenocarcinomas treated by RP. These authors have 
observed a significant increase in frequency of both genomic amplifications and deletions with increasing 
risk strata and of nonsynonymous point mutations. In particular, PGG 1 was haploid, whereas, groups 2–5 
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showed an increasing frequency of polyploidy. Such findings have given support for increasing genomic 
alterations with increasing PGGs [16]. 
Conclusion 
Our findings give further support to the fact that prostate cancer glands with cribriform 
architecture and with glomeruloid features should be considered as a Gleason pattern 4 and not pattern 3. 
In particular, acinar adenocarcinoma with a Gleason score 3 + 3 = 6, based on the 2014 ISUP 
modification, has an excellent prognosis. In addition, the new prognostic grade grouping system 
represents a validated alternative to the Gleason score. 
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